What Is Pulmonary Alveolar Proteinosis?
Pulmonary Alveolar Proteinosis (PAP) is a rare heterogeneous lung disorder characterized by abnormal accumulation of surfactant material within the pulmonary alveoli. It is classified into three major subtypes: autoimmune (acquired), congenital, and secondary PAP. Autoimmune PAP (aPAP, also known as idiopathic/adult PAP) accounts for approximately 90% of all clinical cases. Typical manifestations include insidiously progressive dyspnea, often accompanied by dry cough or scant frothy sputum. Chest imaging displays characteristic diffuse ground-glass opacities and a “crazy paving” pattern. Epidemiological data estimates a global prevalence of 6.87 cases per million individuals.
Pathogenesis
The core pathological cascade of autoimmune PAP is driven by high-titer neutralizing autoantibodies against granulocyte-macrophage colony-stimulating factor (anti-GM-CSF). These autoantibodies specifically bind GM-CSF and block its physiological interaction with GM-CSF receptors on alveolar macrophages, leading to downstream inactivation of critical signaling axes including the JAK-STAT pathway. Impaired GM-CSF signaling disrupts terminal differentiation and functional maturation of alveolar macrophages, drastically attenuating their capacity to phagocytose and catabolize alveolar surfactant.
The homeostatic balance between surfactant production and clearance is broken. Lipoprotein-rich surfactant components (predominantly surfactant proteins SP-A and SP-D) accumulate massively within alveolar lumens, forming eosinophilic lipid-laden deposits. This impairs gas exchange and disrupts local pulmonary innate immunity, resulting in progressive exertional dyspnea and increased susceptibility to opportunistic infections.
Figure Source: Autoimmune Pulmonary Alveolar Proteinosis
Gene Therapy Research
- Gene Editing Therapy For patients with hereditary PAP caused by pathogenic variants in surfactant-related genes (SFTPB, SFTPC, ABCA3 etc.), targeted gene editing can repair or replace mutated gene copies to restore physiological surfactant metabolism.
- AAV-Mediated Gene Delivery Adeno-associated viral vectors are utilized to deliver functional wild-type CSF2 (GM-CSF) transgenes in vivo, to rescue defective alveolar macrophage function.
Preclinical Mouse Models for PAP Research
- Csf2-/- (GM-CSF Knockout) Mice Global ablation of the Csf2 gene recapitulates GM-CSF deficiency, serving as a classic preclinical model to investigate how impaired alveolar macrophage function disrupts surfactant turnover.
- Csf2rb-/- (GM-CSF Receptor β Subunit Knockout) Mice Targeted deletion of the GM-CSF receptor β subunit fully abrogates GM-CSF signal transduction, used to dissect the pathogenic role of blocked GM-CSF signaling in PAP progression.
VeloGene Biotechnology Accelerates Rare Disease Gene Therapy R&D
Gene therapy brings promising therapeutic prospects for rare diseases, yet preclinical mechanism exploration and therapeutic efficacy validation rely heavily on standardized animal models.
Leveraging our proprietary TurboMice™ technology, VeloGene Biotechnology has generated a comprehensive portfolio of rare disease gene-edited mouse models. TurboMice™ resolves two longstanding technical bottlenecks of traditional transgenic strain construction: prolonged breeding cycles and low success rates for complex multi-locus genetic modifications. The platform supports precise editing of nearly any target genomic locus and generates fully homozygous gene-edited mouse lines directly from embryonic stem cells in as little as 2 months.
VeloGene Biotechnology provides custom PAP research mouse models including Csf2-/- knockout mice and Csf2rb-/- knockout mice. Academic and industrial researchers are welcome to reach out for technical consultations!
References
[1] Wang JQ, Hai B, Yang Y. Advances in diagnosis and treatment of pulmonary alveolar proteinosis. Chin Clin Med. 2022, 29(4): 696-700.
[2] McCarthy C, Carey BC, Trapnell BC. Autoimmune Pulmonary Alveolar Proteinosis. Am J Respir Crit Care Med. 2022;205(9):1016-1035. DOI: 10.1164/rccm.202112-2742SO. PMID: 35227171; PMCID: PMC9851473
[3] Piccoli L, Campo I, Fregni CS, et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun. 2015;6:7375. DOI: 10.1038/ncomms8375. PMID: 26077231; PMCID: PMC4477037
Previous Article: Rare Diseases Focus | Issue 22: Phenylketonuria
Next Article: Rare Diseases Focus | Issue 24: Hypophosphatemic Rickets